One of the ongoing Phase I/II trials uses epidermal growth factor receptor 2 (HER2) CAR-T cells to treat advanced-stage ewing’s sarcoma (ES), osteosarcoma (OS), rhabdomyosarcoma (RMS), desmoplastic small round cell tumour (DSRC), and peripheral neuroectodermal tumour positive to the HER2 receptor after chemotherapy (NCT00902044). The gene discussed is ERBB2; the disease is Ewing sarcoma.